The diagnostic performance of the ratio of plasma p‐tau217 to non‐phosphorylated tau is equivalent to or superior to that of clinical CSF tests, enhancing the accessibility of accurate AD diagnosis.23 This evidence concerns the gene MAPT and Alzheimer disease.